Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037525 | 1.00 | LMNA (0.34) | LMNAHTTOGANPC1RAB9A | |
| SCHEMBL20037511 | 1.00 | LMNA (0.34) | LMNAHTTOGANPC1RAB9A | |
| SCHEMBL20038277 | 0.84 | OGA (0.36) | LMNAHTTOGANPC1RAB9A | |
| SCHEMBL20255518 | 0.83 | LMNA (0.34) | LMNAHTTOGAMEN1KMT2A | |
| SCHEMBL20249429 | 0.80 | LCAT (0.33) | LMNAHTTNPC1RAB9AKLF5 | |
| SCHEMBL20249444 | 0.80 | LCAT (0.33) | LMNAHTTNPC1RAB9AKLF5 | |
| SCHEMBL20249446 | 0.80 | LCAT (0.33) | LMNAHTTNPC1RAB9AKLF5 | |
| SCHEMBL3826525 | 0.77 | LMNA (0.43) | LMNAHTTOGANPC1RAB9A | |
| SCHEMBL20038000 | 0.74 | CHRNB2 (0.38) | LMNAHTTOGA | |
| SCHEMBL20038224 | 0.74 | CHRNB2 (0.38) | LMNAHTTOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |